Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gout and cardiovascular disease: crystallized confusion
Aryeh M. Abeles, Michael H. Pillinger
Current Opinion in Rheumatology (2018) Vol. 31, Iss. 2, pp. 118-124
Closed Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

2020 American College of Rheumatology Guideline for the Management of Gout
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls, et al.
Arthritis Care & Research (2020) Vol. 72, Iss. 6, pp. 744-760
Open Access | Times Cited: 654
2020 American College of Rheumatology Guideline for the Management of Gout
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls, et al.
Arthritis & Rheumatology (2020) Vol. 72, Iss. 6, pp. 879-895
Open Access | Times Cited: 553
Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout
Zhilei Wang, Yuchen Li, Wenhao Liao, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 90
Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors
Jun Gao, Xuegui Liu, Bing Zhang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 190, pp. 112077-112077
Closed Access | Times Cited: 44
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease ― Japanese Guideline on the Management of Asymptomatic Hyperuricemia ―
Ichiro Hisatome, Peili Li, Junichiro Miake, et al.
Circulation Journal (2020) Vol. 85, Iss. 2, pp. 130-138
Open Access | Times Cited: 42
Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
Linggen Gao, Bin Wang, Ying Pan, et al.
Clinical Cardiology (2021) Vol. 44, Iss. 7, pp. 907-916
Open Access | Times Cited: 41
Application of Box–Behnken design combined response surface methodology to optimize HPLC and spectrophotometric techniques for quantifying febuxostat in pharmaceutical formulations and spiked wastewater samples
Sk Manirul Haque, Habibur Rahman, Nafisur Rahman, et al.
Microchemical Journal (2022) Vol. 184, pp. 108191-108191
Closed Access | Times Cited: 26
Study on the mechanism of Orthosiphon aristatus (Blume) Miq. in the treatment of hyperuricemia by microbiome combined with metabonomics
Chunsheng Zhu, Hongjuan Niu, Meng Bian, et al.
Journal of Ethnopharmacology (2023) Vol. 317, pp. 116805-116805
Closed Access | Times Cited: 15
The Impact of Different Intensities of Physical Activity on Serum Urate and Gout: A Mendelian Randomization Study
Tangxun Yang, Shilin Bi, Xing Zhang, et al.
Metabolites (2024) Vol. 14, Iss. 1, pp. 66-66
Open Access | Times Cited: 6
Design, synthesis, and biological evaluation of isatin‐indole‐3‐carboxaldehyde hybrids as a new class of xanthine oxidase inhibitors
Atamjit Singh, Shilpa Heer, Komalpreet Kaur, et al.
Archiv der Pharmazie (2022) Vol. 355, Iss. 6
Closed Access | Times Cited: 22
Towards the Development of Dual Hypouricemic and Anti-inflammatory Candidates: Design, Synthesis, Stability Studies and Biological Evaluation of Some Mutual Ester Prodrugs of Febuxostat-NSAIDs
Aya Y. Rashad, Hoda G. Daabees, Mohamed Elagawany, et al.
Bioorganic Chemistry (2023) Vol. 135, pp. 106502-106502
Closed Access | Times Cited: 10
Association Between Gout and Dementia in the Elderly: A Nationwide Population-Based Cohort Study
Kyung Hyun Min, Sang Oh Kang, Su Jin Oh, et al.
American Journal of Geriatric Psychiatry (2021) Vol. 29, Iss. 12, pp. 1177-1185
Closed Access | Times Cited: 22
Mechanism of Biqi Capsules in the treatment of gout based on network pharmacology and experimental verification
Ge Li, Simiao Du, Siya Yan, et al.
Journal of Ethnopharmacology (2024), pp. 118817-118817
Closed Access | Times Cited: 3
Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study
Lisa K. Stamp, Christopher Frampton, Jill Drake, et al.
Arthritis & Rheumatology (2019) Vol. 71, Iss. 10, pp. 1733-1738
Closed Access | Times Cited: 25
Design, synthesis and bioactive evaluation of geniposide derivatives for antihyperuricemic and nephroprotective effects
Mu-xuan Wang, Jia‐Shu Chen, Ruirui Zhang, et al.
Bioorganic Chemistry (2021) Vol. 116, pp. 105321-105321
Closed Access | Times Cited: 19
Gout is associated with elevated risk of erectile dysfunction: a systematic review and meta-analysis
Lianmin Luo, Qian Xiang, Yihan Deng, et al.
Rheumatology International (2019) Vol. 39, Iss. 9, pp. 1527-1535
Closed Access | Times Cited: 20
Amide-based xanthine oxidase inhibitors bearing an N-(1-alkyl-3-cyano-1H-indol-5-yl) moiety: Design, synthesis and structure-activity relationship investigation
Tingjian Zhang, Shun Tu, Xu Zhang, et al.
Bioorganic Chemistry (2021) Vol. 117, pp. 105417-105417
Closed Access | Times Cited: 17
Urate‐lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink
Steven J. Kiddle, Karolina Andersson Sundell, Shira Perl, et al.
Clinical Cardiology (2024) Vol. 47, Iss. 6
Open Access | Times Cited: 2
Febuxostat-based amides and some derived heterocycles targeting xanthine oxidase and COX inhibition. Synthesis, in vitro and in vivo biological evaluation, molecular modeling and in silico ADMET studies
Aya Y. Rashad, Shaymaa E. Kassab, Hoda G. Daabees, et al.
Bioorganic Chemistry (2021) Vol. 113, pp. 104948-104948
Closed Access | Times Cited: 16
N-(3-cyano-1H-indol-5-yl)isonicotinamide and N-(3-cyano-1H-indol-5-yl)-1H-benzo[d]imidazole-5-carboxamide derivatives: Novel amide-based xanthine oxidase inhibitors
Shun Tu, Tingjian Zhang, Yi Zhang, et al.
Bioorganic Chemistry (2021) Vol. 115, pp. 105181-105181
Closed Access | Times Cited: 16
A New Avenue for Enhanced Treatment of Hyperuricemia and Oxidative Stress: Design, Synthesis and Biological Evaluation of Some Novel Mutual Prodrugs Involving Febuxostat Conjugated with Different Antioxidants
Aya Y. Rashad, Hoda G. Daabees, Mohamed Elagawany, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106818-106818
Closed Access | Times Cited: 6
Febuxostat and the Black Box Blues
Aryeh M. Abeles, Michael H. Pillinger
ACR Open Rheumatology (2019) Vol. 1, Iss. 6, pp. 343-344
Open Access | Times Cited: 12
Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on In Vitro Hepatic Lipogenesis-Related Gene Expression
Yi‐Jen Fang, Tien‐Yuan Wu, Cheng‐Li Lin, et al.
Mediators of Inflammation (2020) Vol. 2020, pp. 1-13
Open Access | Times Cited: 11
Genetically predicted physical activity is associated with lower serum urate concentrations
Ying Guan, Jiahe Wei, Lifeng Meng, et al.
Genes & Genomics (2022) Vol. 44, Iss. 7, pp. 843-853
Closed Access | Times Cited: 7
A Brief Review of Natural Products with Urate Transporter 1 Inhibition for the Treatment of Hyperuricemia
Qianghua Yuan, Yuan Cheng, Rong Sheng, et al.
Evidence-based Complementary and Alternative Medicine (2022) Vol. 2022, pp. 1-16
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top